Aditxt Inc. Completes Reverse Split, Stock Price Drops
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 Jan 26
Aditxt Inc. experienced a significant drop of 24.66% in its stock price, crossing below the 5-day SMA, reflecting a negative market reaction.
The decline follows the company's recent execution of a 1-for-113 reverse stock split aimed at maintaining compliance with Nasdaq's minimum bid price requirements. While the reverse split was intended to enhance market appeal, it appears to have led to investor concerns about the company's future financing capabilities and overall market confidence.
This price movement may indicate a shift in investor sentiment, as the upcoming special shareholder meeting on January 30, 2026, could bring further clarity on capital and governance proposals, including the authorization of convertible preferred stock.
Analyst Views on ADTX
About ADTX
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
